Compounds and compositions to control abnormal cell growth
AssigneeCanCure Laboratories, LLC
InventorZoltan Kiss
Life of this patent
Estimating the term…
Loading patent…
AssigneeCanCure Laboratories, LLC
InventorZoltan Kiss
Estimating the term…
A class of compounds commonly containing a trialkylammonium group have been synthesized and characterized as anticancer compounds. A representative of this class, N,N-diethyl-N-methyl-2-[(9-oxo-9H-thioxanthen-2-yl)methoxy]ethanaminium iodide (CCDTHT) was shown in various tumor models to decrease tumor volume, enhance the effects of other chemotherapeutic agents including cisplatin, reduce chemotherapy-induced loss of body weight, and increase survival of animals co-treated with toxic amounts of cisplatin. CCDTHT had even greater effects on tumor volume, body weight, and survival when administered to animals together with the human protein placental alkaline phosphatase. These trialkylammonium group-containing compounds and alkaline phosphatases, particularly in combination with each other and other therapies, may be used to treat cancer and other cell proliferative diseases.
A method of treating a patient with a tumor, the method comprising administering to the patient a pharmaceutical comprising a heterocyclic compound having one or two quaternary ammonium groups to reduce the volume of the tumor, the compound having the formula:
Dependencies are inferred from the claim text.